Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC/CBD oral solution for symptom distress in advanced cancer
ACTRN12622000083796Phase 3Recruiting
- Sponsor
- Mater Misericordiae University Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cancer comparing THC/CBD oral solution with Placebo oral solution (2 arms). Primary endpoint: Change from baseline in total symptom distress score. Started Dec 2022; status: recruiting.
02
Drugs
dronabinolcannabidiol
03
Conditions
cancer
Beyond the preview
Go deeper on ACTRN12622000083796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000083796.